Insider · CIK 0001774690
Thomas Leggett
Files at STOK (Stoke Therapeutics, Inc.). First filing Mar 19, 2026, latest Mar 19, 2026.
In brief
Thomas Leggett files SEC Form 4 as CFO at STOK (Stoke Therapeutics, Inc.). Since Mar 19, 2026, Thomas Leggett has reported 0 open-market buys worth $0 and 1 open-market sell worth $147k, the latest filed on Mar 19, 2026.
A track record needs three past buys with six months of prices behind them; Thomas Leggett has 0, so none is measured yet.
The newest scored trade: sold $147k of STOK on Mar 17, 2026, filed Mar 19, 2026, scored 58 (moderate). In the last 12 months: 0 buys worth $0 and 1 sell worth $147k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
STOK: Stoke Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 58Moderate | Stoke Therapeutics, Inc. | $147k 4,578 shares | -31% | +457% from low-14% from high |
Transactions
Every row this insider has filed, 9 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 17, 2026 | STOK Stoke Therapeutics, Inc. | SOpen-market sale Common Stock | -1,274 | $32.74 | $42k | 13,476 | Mar 19, 2026 |
| Mar 17, 2026 | STOK Stoke Therapeutics, Inc. | SOpen-market sale Common Stock | -922 | $33.38 | $31k | 12,554 | Mar 19, 2026 |
| Mar 18, 2026 | STOK Stoke Therapeutics, Inc. | SOpen-market sale Common Stock | -2,173 | $31.28 | $68k | 10,381 | Mar 19, 2026 |
| Mar 18, 2026 | STOK Stoke Therapeutics, Inc. | SOpen-market sale Common Stock | -172 | $31.79 | $5,468 | 10,209 | Mar 19, 2026 |
| Mar 18, 2026 | STOK Stoke Therapeutics, Inc. | SOpen-market sale Common Stock | -37 | $32.85 | $1,215 | 10,172 | Mar 19, 2026 |
| Mar 15, 2026 | STOK Stoke Therapeutics, Inc. | MOption exercise Common Stock | +14,750 | $0.00 | $0 | 14,750 | Mar 17, 2026 |
| Mar 15, 2026 | STOK Stoke Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -14,750 | $0.00 | $0 | 44,250 | Mar 17, 2026 |
| Feb 17, 2026 | STOK Stoke Therapeutics, Inc. | AGrant or award Employee Stock Option (Right to Buy)derivative | +60,000 | $0.00 | $0 | 60,000 | Feb 19, 2026 |
| Feb 17, 2026 | STOK Stoke Therapeutics, Inc. | AGrant or award Restricted Stock Unitsderivative | +40,000 | $0.00 | $0 | 40,000 | Feb 19, 2026 |
Questions about Thomas Leggett
Answered from the filings on this page, as of the latest one.
Is Thomas Leggett buying or selling?
In the last 12 months Thomas Leggett reported 0 open-market buys worth $0 and 1 open-market sell worth $147k on SEC Form 4; the latest was sold $147k of STOK on Mar 17, 2026. Grants, option exercises and tax withholding are not counted.
How did Thomas Leggett's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Thomas Leggett has 0.
Where does Thomas Leggett file Form 4?
Thomas Leggett has filed Form 4 at STOK (Stoke Therapeutics, Inc.) as Chief Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.